Skip to content
ASCIENDE
ES

The Asciende advantage

Free Mexico shipping from $2,500 MXN

Shipping details
Volume pricingShipping protection included

Comparison · GHRH analog

CJC-1295 DAC vs Sermorelin

These compounds share a catalog class. That grouping makes their declared properties useful to compare, but does not establish experimental or clinical interchangeability.

For in vitro and laboratory research only. Not for human or veterinary use, diagnosis or treatment. These research materials have not been evaluated by COFEPRIS.

What distinguishes these compounds

Sermorelin is the amidated human GHRH(1-29) fragment. CJC-1295 DAC is an analogue of that fragment with an attached albumin affinity complex. The additional modification is part of the chemical identity, even though both entries describe the GHRH receptor pathway.

The catalog declares a sequence, molecular formula and molecular weight for sermorelin, while those fields are not declared for CJC-1295 DAC. Missing declarations should remain visible rather than being filled with values from the related peptide.

What they are

CJC-1295 DAC: CJC-1295 DAC is an analog of the 1-29 fragment of growth hormone-releasing hormone, with an attached maleimide-type albumin affinity complex. In research literature, it binds to the GHRH receptor and acts as an agonist of that pathway. It has been studied in models of prolonged exposure of the somatotropic axis in preclinical research.

Sermorelin: Sermorelin is the amidated 1-29 fragment of human growth hormone-releasing hormone. In research models, it binds to the GHRH receptor and acts as an agonist of that pathway in the anterior pituitary. It has been investigated in models of somatotropic axis signaling in rodent studies.

Mechanisms described in the literature

CJC-1295 DAC: The affinity group forms a covalent bond with serum albumin in in vitro studies, modifying the peptide's exposure profile. The molecular target remains the GHRH receptor, which is coupled to Gs protein.

Sermorelin: The 1-29 fragment retains the minimal region described for binding to the GHRH receptor. Receptor activation increases cyclic AMP in cellular models.

Declared chemical identity, field by field

A dash means that the catalog does not declare that field for the compound. If neither entry declares a field, the row is omitted. A label purity specification of ≥ 99 % is not an analytical result; results must come from the certificate for the relevant batch.

CJC-1295 DAC vs Sermorelin: declared technical information
FieldCJC-1295 DACSermorelin
Chemical nameGHRH(1-29) analog with an albumin affinity complex (DAC)Human GHRH(1-29) amide
Sequence—Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Molecular formula—C149H246N44O42S
Molecular weight—3357.9 Da
CAS number446262-90-486168-78-7
FormLyophilized powderLyophilized powder
AppearanceWhite to off-white solidWhite to off-white solid
SolubilitySoluble in sterile water and bacteriostatic waterSoluble in sterile water and bacteriostatic water
Storage−20 °C, protected from light−20 °C, protected from light
Stability after reconstitutionKeep refrigerated at 2–8 °C and use within the period defined by the laboratory protocolKeep refrigerated at 2–8 °C and use within the period defined by the laboratory protocol

Laboratory handling: CJC-1295 DAC

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Laboratory handling: Sermorelin

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Catalog presentations

Consult each product page for its current presentations, availability, batch documentation and price. This comparison does not freeze commercial information in the research text.

Complete research references

The compendium entries contain the extended definitions, research context and indexed bibliography for each compound. The comparison organizes declared information; it does not replace study-specific interpretation or batch identity evidence.

Sources

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. — J Clin Endocrinol Metab (2006); PMID 16352683; DOI 10.1210/jc.2005-1536
  2. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. — J Clin Endocrinol Metab (2006); PMID 16352683; DOI 10.1210/jc.2005-1536
  3. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. — J Clin Endocrinol Metab (2006); PMID 17018654; DOI 10.1210/jc.2006-1702
  4. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. — J Clin Endocrinol Metab (2006); PMID 17018654; DOI 10.1210/jc.2006-1702
  5. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. — Growth Horm IGF Res (2009); PMID 19386527; DOI 10.1016/j.ghir.2009.03.001
  6. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. — Growth Horm IGF Res (2009); PMID 19386527; DOI 10.1016/j.ghir.2009.03.001
  7. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. — Endocrinology (2005); PMID 15817669; DOI 10.1210/en.2004-1286
  8. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. — Endocrinology (2005); PMID 15817669; DOI 10.1210/en.2004-1286
  9. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. — BioDrugs (1999); PMID 18031173; DOI 10.2165/00063030-199912020-00007
  10. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. — BioDrugs (1999); PMID 18031173; DOI 10.2165/00063030-199912020-00007
  11. Super-active analogs of growth hormone-releasing factor (1-29)-amide. — Biochem Biophys Res Commun (1984); PMID 6231028; DOI 10.1016/0006-291x(84)91647-4
  12. Super-active analogs of growth hormone-releasing factor (1-29)-amide. — Biochem Biophys Res Commun (1984); PMID 6231028; DOI 10.1016/0006-291x(84)91647-4
  13. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. — Transl Androl Urol (2020); PMID 32257855; DOI 10.21037/tau.2019.11.30
  14. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. — Transl Androl Urol (2020); PMID 32257855; DOI 10.21037/tau.2019.11.30
  15. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. — Front Endocrinol (Lausanne) (2026); PMID 42395176; DOI 10.3389/fendo.2026.1822475
  16. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. — Front Endocrinol (Lausanne) (2026); PMID 42395176; DOI 10.3389/fendo.2026.1822475
  17. Pharmacokinetic evaluation of superactive analogues of growth hormone-releasing factor (1-29)-amide. — Peptides (1988); PMID 2896343; DOI 10.1016/0196-9781(88)90029-0
  18. Pharmacokinetic evaluation of superactive analogues of growth hormone-releasing factor (1-29)-amide. — Peptides (1988); PMID 2896343; DOI 10.1016/0196-9781(88)90029-0
  19. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. — J Clin Invest (1989); PMID 2565342; DOI 10.1172/JCI114049
  20. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. — J Clin Invest (1989); PMID 2565342; DOI 10.1172/JCI114049
Ayuda